Myeloma Data Presented at ASCO Highlight Continued Evolution of ...
OncLive - 09 Jul 2024Noa Biran, MD, discusses key data from clinical trials in multiple myeloma presented at the 2024 ASCO Annual Meeting.
Multiple myeloma
Noa Biran, MD, discusses key data from clinical trials in multiple myeloma presented at the 2024 ASCO Annual Meeting.
Extramedullary disease but not paraskeletal disease portends inferior outcomes after CAR T cell therapy in multiple myeloma
Nature - 03 May 2025Extramedullary disease but not paraskeletal disease portends inferior outcomes after CAR T cell therapy in multiple myeloma ...
Multiple myeloma is treatable, not curable. Is that set to change?
Fred Hutchinson Cancer Center - 03 Apr 2025Multiple myeloma is treatable, not curable. Is that set to change? ...
Use of Ruxolitinib to Resolve Ciltacabtagene Autoleucel Induced Parkinsonism in Patients With Multiple Myeloma
The ASCO Post - 02 May 2025Use of Ruxolitinib to Resolve Ciltacabtagene Autoleucel Induced Parkinsonism in Patients With Multiple Myeloma ...
Exploring secondary extramedullary myeloma disease: a five-predictor scoring system with spotlight on double-hit cytogenetics
BMC Medicine - 02 May 2025Exploring secondary extramedullary myeloma disease: a five-predictor scoring system with spotlight on double-hit cytogenetics ...
Study offers a potential new strategy to improve treatment responses in multiple myeloma patients
News-Medical - 15 Apr 2025Study offers a potential new strategy to improve treatment responses in multiple myeloma patients ...
Smoldering multiple myeloma: What it is, how it progresses and the latest research
Mayo Clinic News Network - 22 Apr 2025Smoldering multiple myeloma: What it is, how it progresses and the latest research ...
Cilta-cel: A new era in multiple myeloma treatment
Drug Target Review - 29 Jan 2025Cilta-cel: A new era in multiple myeloma treatment ...
Advances in Multiple Myeloma Research
National Cancer Institute (.gov) - 06 Mar 2025Advances in Multiple Myeloma Research ...
1 gene is key to drug resistance in multiple myeloma
futurity.org - 24 Apr 20251 gene is key to drug resistance in multiple myeloma ...
Dr Sobh on the Effects of NSD2 Overexpression in Multiple Myeloma
OncLive - 29 Apr 2025Dr Sobh on the Effects of NSD2 Overexpression in Multiple Myeloma ...
Novel target for cell therapy may extend options for multiple myeloma patients
Nature - 30 Apr 2025Novel target for cell therapy may extend options for multiple myeloma patients ...
CD56 expression modulates NAD+ metabolic landscape and predicts sensitivity to anti-CD38 therapies in multiple myeloma
Nature - 02 May 2025CD56 expression modulates NAD+ metabolic landscape and predicts sensitivity to anti-CD38 therapies in multiple myeloma ...
Knowledge, attitude and practice towards multiple myeloma among medical staff in Enshi Region
Nature - 27 Jan 2025Knowledge, attitude and practice towards multiple myeloma among medical staff in Enshi Region ...
Real-world treatment patterns for teclistamab and talquetamab in multiple myeloma (MM): experience from 609 patients
Nature - 08 Apr 2025Real-world treatment patterns for teclistamab and talquetamab in multiple myeloma (MM): experience from 609 patients ...
PCMMD: A Novel Dataset of Plasma Cells to Support the Diagnosis of Multiple Myeloma
Nature - 27 Jan 2025PCMMD: A Novel Dataset of Plasma Cells to Support the Diagnosis of Multiple Myeloma ...
A systematic epidemiological trends analysis study in global burden of multiple myeloma and 29 years forecast
Nature - 16 Jan 2025A systematic epidemiological trends analysis study in global burden of multiple myeloma and 29 years forecast ...
Clonal plasma cell proportion in the synthetic phase identifies a unique high-risk cohort in multiple myeloma
Nature - 18 Feb 2025Clonal plasma cell proportion in the synthetic phase identifies a unique high-risk cohort in multiple myeloma ...
Deciphering response dynamics and treatment resistance from circulating tumor DNA after CAR T-cells in multiple myeloma
Nature - 20 Feb 2025Deciphering response dynamics and treatment resistance from circulating tumor DNA after CAR T-cells in multiple myeloma ...
Venetoclax-based treatment combinations in relapsed/refractory multiple myeloma: practice patterns and impact of secondary cytogenetic abnormalities on outcomes | Blood Cancer Journal
Nature - 04 Apr 2025Venetoclax-based treatment combinations in relapsed/refractory multiple myeloma: practice patterns and impact of secondary cytogenetic abnormalities on outcomes | Blood Cancer Journal ...